Elnaz Malekahmadi
Family · Newport Beach, CANPI 1114495710
Payments from drug & device makers
Across 220 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$862
- Otsuka America Pharmaceutical, Inc.$544
- AstraZeneca$479
- Bayer$444
- Fresenius USA Marketing, Inc.$366
- OPKO Pharmaceuticals, LLC$218
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,616100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 38 | $862 |
| Otsuka America Pharmaceutical, Inc. | 25 | $544 |
| AstraZeneca(2 entities) | 22 | $479 |
| Bayer | 28 | $444 |
| Fresenius USA Marketing, Inc. | 17 | $366 |
| OPKO Pharmaceuticals, LLC | 10 | $218 |
| Novo Nordisk | 9 | $182 |
| Boehringer Ingelheim | 10 | $181 |
| Amgen | 8 | $177 |
| Ardelyx, Inc. | 8 | $170 |
| Aurinia Pharma U.S., Inc. | 7 | $144 |
| Calliditas Therapeutics US Inc. | 6 | $128 |
| Amarin Pharma, Inc. | 6 | $127 |
| Novartis | 5 | $117 |
| Apellis Pharmaceuticals, Inc. | 4 | $86 |
| Mallinckrodt Hospital Products Inc. | 2 | $68 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Viiv Healthcare Company | 2 | $43 |
| Sanofi | 1 | $31 |
| Shield Therapeutics Inc | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 1 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| GSK | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $16 |
How this compares
$4,616 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 46 | $41,590 |
| VeltassaPatiromer Calcium Sorbitex | 24 | $25,935 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $10,771 |
| Sevelamer Carbonate | 19 | $3,765 |
| Potassium Chloride | 57 | $2,127 |
| Bumetanide | 22 | $1,853 |
| Hydralazine Hcl | 41 | $689 |
| Amlodipine Besylate | 106 | $652 |
| Clonidine | 16 | $616 |
| Losartan Potassium | 55 | $490 |
| Valsartan | 15 | $416 |
| Cefdinir | 26 | $382 |
| Calcitriol | 15 | $330 |
| Desmopressin Acetate | 11 | $291 |
| Nifedipine ErNifedipine | 14 | $290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $479 | $52,36258 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Newport Beach
- Carol ChowNewport Beach$129K
- Anisa MunshiNewport Beach$120K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.